Skip to main content

Table 2 Side effects of BCNU-based chemotherapy classified according to CTCAE v.2.0

From: Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

Side Effects (%) CTCAE I CTCAE II CTCAE III CTCAE IV
Patients with side effects 51 (31) 23 (14) 8 (5) 7 (4)
Leukopenia 38 (22,8) 17 (10,2) 2 (1,2) 1 (0,6)
Thrombocytopenia 35 (21) 5 (3) 5 (3) 1 (0,6)
Anemia 16 (9,6) - 1 (0,6) -
Nausea/Vomitus 3 (1,8) 2 (1,2) - -
Fatigue 1 (0,6) - - -
Obstipation/Diarrhea 2 (1,2) - - -
Pulmonary Fibrosis - - - 1 (0,6)
Thromboembolism - - 1 (0,6) 1 (0,6)
Hemorrhage - - - 1 (0,6)
Injection Site Reaction 1 (0,6) 2 (1,2) 1 (0,6) -
Othersa 4 (2,4) 2 (1,2) 2 (1,2) 1 (0,6)
  1. aSide effects classified as “others” were found in timely but not necessarily causal relation to BCNU administration and consisted of weight loss/loss of appetite CTCAE I (1.2 %), arterial hypotension CTCAE I (0.6 %), neuropathic pain CTCAE I (0.6 %), newly observed cranial nerve deficit CTCAE II (0.6 %), photophobia CTCAE II (0.6 %) and hallucinations CTCAE III (0.6 %), anaphylaxis CTCAE III (0.6 %) and isolated elevation of liver transaminases CTCAE IV (0.6 %)